About this Gilbert joint guide

Your exam decides what belongs in the treatment talk

Write down the motion that hurts and how long soreness lasts. Note swelling, weakness, catching, and lost sleep. Older joint reports, X-rays, and your pill list can also help. The doctor can then compare those details with the exam.

At QC Kinetix, medical providers—the trained people who examine you—may offer regenerative treatments, including care prepared from drawn blood, after reviewing joint soreness. The exam may instead point toward exercise, medicine, more testing, or surgery. This page can't make that choice for you.

Ask how much pain relief might occur and how long that relief could last. Get the full price, time needed afterward, and other choices too. If the clinic claims new cartilage grew, ask for an X-ray or scan from before and after treatment.

Pain relief and new tissue aren't the same result.

You don't need to learn every medical term first. Bring your questions and name the task that's become hard. A clear example can keep the visit about your daily life. You won't need an answer before the exam, and someone else's result can't tell you whether the shot suits your joint. It isn't a choice this page can make, and it shouldn't replace your doctor's advice.

Sources

1. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

2. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis is the orthopedic profession's own GRADE-style appraisal of the same options a regenerative clinic sells; it is the benchmark against which any 'regenerative' claim on this topic should be read, and it rates the strongest support for exercise, weight loss and self-management rather than for injectables.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. The Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.